Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.

By L. Lannfelt, Kaj Blennow, Henrik Zetterberg, Stellan Båtsman, D. Ames, J. Harrison, Colin L. Masters, S. Targum, Ashley I. Bush, R. Murdoch and 2 more. Lancet Neurology, 2008

655 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Copper homeostasis and cuproptosis in health and disease (2022, positive): “Moreover, serum-free Cu levels are known to be elevated with aging,92 and both total and free Cu levels are increased in the serum of patients with AD compared to healthy controls.93–95 Importantly, high levels of Cu have been measured in senile plaques in patients with AD.96 Excess Cu could bind di”
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives (2010, neutral): “, showed a dose-dependent reduction in CSF Aβ 42 level”
Therapeutics of Alzheimer's disease: Past, present and future. (2014, positive): “The decrease in CSF Ab levels and cognitive outcome patternwere similar to clioquinol, but there was a statistically significant improvement in executive function Z scores (Lannfelt et al., 2008).”
Alzheimer's disease: strategies for disease modification (2010, background): “Prana is advancing a second-generation compound, PBT2, in Phase II trial”
Zinc in the physiology and pathology of the CNS (2009, background): “In a Phase II trial of PBT2 in 78 patients with early AD, the agent decreased CSF amyloid-β 42 levels, and there was a significant time- and dose-dependent improvement above baseline in performance in executive tests of the neuropsychological test battery over the 12 weeks of the stud”